ASCO 26: Three strong Pfizer Phase 3s, with Johanna Bendell

At this year’s ASCO Annual Meeting, Pfizer had three major Phase 3 oral presentations: CROWN, TALAPRO-3, and BREAKWATER, each paired with simultaneous publications in leading medical journals.

Pharmaphorum caught up with Johanna Bendell, Pfizer’s chief development officer for oncology, to learn about the clinical impact of these landmark studies, what they mean for patients, and how Pfizer is evolving its pipeline strategy. She discusses the unprecedented seven-year survival data for lorlatinib in the CROWN trial, the strong progression-free survival data in HRR-mutated castration-sensitive prostate cancer in TAPRO-3, and both PFS and OS data on encorafenib in the BREAKWATER trial.

She also shares her perspective on the growing role of artificial intelligence in transforming oncology research and care. Check out the full video below.